FDA Retatrutide Approval 2026: Market Sits at 27%

Polymarket traders have pushed Retatrutide’s 2026 FDA approval odds from a floor of 12 cents to 27 cents over the past month. That’s not conviction. That’s a market repricing from near-impossible to unlikely, and the difference matters. The data doesn’t care about the politics, and right now the data says Eli Lilly still has significant regulatory runway left before any approval lands inside a calendar year.

The FDA approves Retatrutide this year market sits at 27% YES as of April 2, 2026, with NO holding at 73%. The contract resolves December 31, 2026. Total volume is $543,852 across the market’s life, with $301 traded in the last 24 hours. That thin recent activity means a single meaningful data release can move this price sharply in either direction.

How the Retatrutide FDA Approval Contract Works

This contract resolves YES if the FDA grants approval for Retatrutide, Eli Lilly’s GIP/GLP-1/glucagon triple-agonist, at any point before December 31, 2026. Resolution NO means approval did not occur within the calendar year. The resolution source is market resolution tied to official FDA action.

• YES: FDA grants Retatrutide approval before December 31, 2026. Price: $0.27. Probability: 27%. Resolves: December 31, 2026.
• NO: FDA does not approve Retatrutide in 2026. Price: $0.73. Probability: 73%. Resolves: December 31, 2026.

NO buyers need one of two things: FDA inaction through year-end, or a Complete Response Letter that kicks the timeline into 2027 or beyond. What threatens NO is a surprise priority review designation, an accelerated approval pathway, or Phase 3 data so strong that Lilly files a New Drug Application ahead of current expectations. NO is the probabilistic default here, but it is not a certainty. The FDA’s approval timeline for obesity drugs has shown it can move fast when data is compelling.

Sponsored Partner

Momentum and Market Signals on Retatrutide

The momentum picture is cautiously positive for YES. The 1-hour change is flat, the 24-hour change is plus 3.5%, and the 7-day change is plus 4.0%. Combined, those signals point to a slow, sustained drift upward rather than a single catalyst spike. The March 12 jump of 10 points in one day was the sharpest single move in recent history, likely tied to Phase 3 trial updates or Lilly investor communications, though no specific public announcement has been confirmed in the data provided.

Here’s what the measurements are telling us about conviction: $543,852 in total volume is real but modest for a drug approval market. The 24-hour volume of $301 is essentially zero. Liquidity sits at $3,651. This is a thin market. The market is pricing uncertainty, not science, and with this little active trading, a single large YES or NO bet could move the price by several percentage points without reflecting any new clinical or regulatory information. Treat the current 27% as a signal, not a verdict.

KEY FACTORS:

• 24-hour price change: Plus 3.5% on April 2, 2026. Modest upward drift suggests traders are leaning toward slightly better approval odds without a specific catalyst.
• 7-day price change: Plus 4.0%. Consistent directional movement over a week indicates sustained, if quiet, repositioning toward YES.
• 30-day low of 0.12: The market was pricing near-zero approval probability as recently as early March. The recovery to 0.27 is substantial in percentage terms.
• 24-hour volume of $301: Thin liquidity means this price is fragile. New trial data or an FDA announcement would reprice the contract fast.
• Market open price of 0.24: The contract opened April 2 at 24 cents and moved to 27 cents intraday, a 12.5% single-day gain in implied probability.

Lines Analysis: Retatrutide and the FDA Calendar Problem

The case for YES at 27% rests on Retatrutide’s clinical profile and Eli Lilly’s regulatory momentum. Phase 2 data showed weight loss of up to 24% of body weight at the highest dose, which is stronger than approved GLP-1 competitors at comparable trial stages. Lilly has deep FDA experience after Tirzepatide’s approval pathway, and that institutional knowledge accelerates submissions. If Phase 3 TRIUMPH trial data reads out strongly in mid-2026 and Lilly files an NDA promptly, a late-2026 approval under priority review is not mathematically impossible. The market is pricing that scenario at roughly one-in-four.

The case for NO at 73% is built on calendar math and regulatory process. FDA standard review runs 10 to 12 months from NDA submission. As of April 2, 2026, no NDA submission for Retatrutide has been publicly confirmed. Without a confirmed submission already in queue, the standard pathway almost certainly cannot deliver a 2026 approval. Priority review compresses that to 6 months, but priority designation requires either a rare disease claim or clear advantage over existing therapy. The obesity drug class is now crowded. FDA reviewers have Tirzepatide and Semaglutide as reference points, raising the evidentiary bar for priority status.

SIGNALS TO MONITOR:

• Eli Lilly NDA submission announcement: A confirmed filing to the FDA would be the single largest bullish catalyst. Without it, 2026 approval stays improbable.
• TRIUMPH Phase 3 trial data readout: Topline results expected in mid-2026. Strong weight loss and cardiovascular endpoints would push YES materially higher.
• FDA priority review designation: If granted, compresses the review clock to roughly 6 months. This is the scenario where 2026 approval becomes genuinely plausible.
• FDA Complete Response Letter to any Lilly application: Any CRL in the obesity or metabolic space signals heightened scrutiny and would push Retatrutide’s odds lower.
• Competing approvals (Semaglutide oral, CagriSema): If FDA clears another obesity agent in 2026, it could signal bandwidth and favorable agency posture, a mild positive for YES.

The $543,852 in total market volume reflects real trader interest in this outcome, but the current 24-hour freeze tells you the market is waiting. Nobody is making big moves until Phase 3 data or an NDA announcement forces a reprice. The data currently favors NO by a substantial margin, not because Retatrutide’s science is weak, but because the regulatory calendar is unforgiving and no confirmed submission is on record.

LINES VERDICT

NO HOLDS THROUGH MID-YEAR

The regulatory timeline has not accelerated enough to make 2026 approval probable. No confirmed NDA submission means the calendar is already working against YES.

What the market says: 27% implies traders see roughly a one-in-four chance of approval this year. That probability is vulnerable to collapse if Phase 3 data disappoints or Lilly signals a 2027 filing timeline as the December 31 resolution date approaches.

Key unknown: An Eli Lilly NDA submission announcement is the single event that would reprice this contract dramatically. Confirmation of filing would push YES toward 50% or higher overnight. Absence of a filing announcement by late summer would likely push YES back toward the March low near 12%.